| Company Name: |
Borenpharm Co., Ltd
|
| Tel: |
027-65563561 |
| Email: |
sales@borenpharm.com |
| Products Intro: |
Product Name:3,6,9,12-tetraoxatetradecane-1,14-diyl diacrylate
CAS:59256-52-9
Purity:95% HPLC Package:1g; 5g
|
| Company Name: |
Aikon International Limited
|
| Tel: |
025-66113011 13155353615 |
| Email: |
qzhang@aikonchem.com |
| Products Intro: |
Product Name:2-Propenoic acid,3,6,9,12-tetraoxatetradecane-1,14-diyl ester (9CI)
CAS:59256-52-9
Purity:95+% Package:1g;5g;10g
|
| Company Name: |
Shaanxi borno biotechnology co., LTD
|
| Tel: |
+86-13759708231 |
| Email: |
asherw9@hotmail.com |
| Products Intro: |
Product Name:3,6,9,12-tetraoxatetradecane-1,14-diyl diacrylate
CAS:59256-52-9
Purity:99% HPLC Package:可分装
|
| Company Name: |
Shanghai Kaiwei Chemical Technology Co., Ltd.
|
| Tel: |
021-58461859 15821823057 |
| Email: |
service@aiviche.com |
| Products Intro: |
Product Name:3,6,9,12-tetraoxatetradecane-1,14-diyl diacrylate
CAS:59256-52-9
Purity:95% Package:1g;1kg
|
|
| | 3,6,9,12-tetraoxatetradecane-1,14-diyl diacrylate Basic information |
| Product Name: | 3,6,9,12-tetraoxatetradecane-1,14-diyl diacrylate | | Synonyms: | 3,6,9,12-tetraoxatetradecane-1,14-diyl diacrylate;Bispropenoic acid 3,6,9,12-tetraoxatetradecane-1,14-diyl ester;Einecs 261-677-8;2-Propenoic acid, 1,1'-(3,6,9,12-tetraoxatetradecane-1,14-diyl) ester;Bis-acrylate-PEG5;2-Propenoic acid,3,6,9,12-tetraoxatetradecane-1,14-diyl ester (9CI);14-(prop-2-enoyloxy)-3,6,9,12-tetraoxatetradecan-1-yl prop-2-enoate | | CAS: | 59256-52-9 | | MF: | C16H26O8 | | MW: | 346.37 | | EINECS: | 2616778 | | Product Categories: | | | Mol File: | 59256-52-9.mol |  |
| | 3,6,9,12-tetraoxatetradecane-1,14-diyl diacrylate Chemical Properties |
| | 3,6,9,12-tetraoxatetradecane-1,14-diyl diacrylate Usage And Synthesis |
| Biological Activity | Bis-acrylate-PEG5 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. | | References | [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
| | 3,6,9,12-tetraoxatetradecane-1,14-diyl diacrylate Preparation Products And Raw materials |
|